Wells Fargo
PLX icon

Wells Fargo’s Protalix BioTherapeutics PLX Stock Holding History

Wells Fargo’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$157K Buy
67,549
+41,027
+155% +$86.9K ﹤0.01% 5335
2026
Q1 		$57.6K Sell
26,522
-52,480
-66% -$130K ﹤0.01% 5405
2025
Q4 		$142K Buy
79,002
+36,171
+84% +$74K ﹤0.01% 5243
2025
Q3 		$95.1K Buy
42,831
+6,797
+19% +$11.1K ﹤0.01% 5345
2025
Q2 		$53.3K Buy
+36,034
New +$73.7K ﹤0.01% 5482
2024
Q2 		– Sell
-23,369
Closed -$29.4K – 7325
2024
Q1 		$29.4K Buy
23,369
+3,439
+17% +$5.13K ﹤0.01% 5458
2023
Q4 		$35.5K Buy
19,930
+4,010
+25% +$6.24K ﹤0.01% 5400
2023
Q3 		$26.4K Sell
15,920
-5,074
-24% -$9.11K ﹤0.01% 5482
2023
Q2 		$42K Buy
+20,994
New +$50K ﹤0.01% 5493
2019
Q2 		– Sell
-70
Closed – – 6550
2019
Q1 		$0 Hold
70
– – ﹤0.01% 6354
2018
Q4 		$0 Sell
70
-10,000
-99% -$47.5K ﹤0.01% 6559
2018
Q3 		$73K Hold
10,070
– – ﹤0.01% 5471
2018
Q2 		$43K Hold
10,070
– – ﹤0.01% 5637
2018
Q1 		$54K Hold
10,070
– – ﹤0.01% 5541
2017
Q4 		$67K Hold
10,070
– – ﹤0.01% 5455
2017
Q3 		$58K Hold
10,070
– – ﹤0.01% 5418
2017
Q2 		$84K Hold
10,070
– – ﹤0.01% 5244
2017
Q1 		$137K Buy
10,070
+10,000
+14,286% +$89.9K ﹤0.01% 5040
2016
Q4 		$0 Hold
70
– – ﹤0.01% 6401
2016
Q3 		$0 Hold
70
– – ﹤0.01% 6308
2016
Q2 		$0 Hold
70
– – ﹤0.01% 6269
2016
Q1 		$1K Hold
70
– – ﹤0.01% 6106
2015
Q4 		$1K Hold
70
– – ﹤0.01% 6105
2015
Q3 		$1K Buy
+70
New +$1.11K ﹤0.01% 6070

Other funds holding PLX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SWP
Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Wells Fargo's PLX Position: Q2 2026 in Review

Wells Fargo increased its Protalix BioTherapeutics (PLX) stake by 155% in Q2 2026, buying an estimated $86.9K and bringing the position to 67,549 shares worth $157K. The position accounts for ﹤0.01% of the portfolio, ranked #5335.

Wells Fargo first reported a position in PLX in Q3 2015 and has held it in 24 quarters since. 102 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

  • Wells Fargo held 67,549 shares of Protalix BioTherapeutics worth $157K as of Q2 2026.
  • Wells Fargo bought 41,027 Protalix BioTherapeutics shares in Q2 2026, an estimated $86.9K.
  • Protalix BioTherapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #5335 holding.
  • Wells Fargo first reported a position in Protalix BioTherapeutics in Q3 2015 and has held it in 24 quarters since.
  • 102 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.